A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • Vol. 71, Issue 10 • 2020
Antimalarial efficacy of MMV390048, an inhibitor of phosphatidylinositol 4-kinase.
Science translational medicine • Vol. 9, Issue 387 • 2017
Targeting Plasmodium PI(4)K to eliminate malaria.
Nature • Vol. 504, Issue 7479 • 2013
Cell-based medicinal chemistry optimization of high throughput screening hits for orally active antimalarials. Part 2: hits from SoftFocus kinase and other libraries.
Journal of medicinal chemistry • Vol. 56, Issue 20 • 2013
